Evidence map›Paper›PMID 36986702›Full record

ArticlePharmaceutics2023

Terbinafine Nanohybrid: Proposing a Hydrogel Carrying Nanoparticles for Topical Release.

Louise Lacalendola Tundisi, Janaína Artem Ataide, Jéssica Heline Lopes da Fonseca, Luiza Aparecida Luna Silvério, Marcelo Lancellotti, Ana Cláudia Paiva-Santos, Marcos Akira d'Ávila, Daniel S Kohane, Priscila Gava Mazzola

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Louise Lacalendola TundisiFaculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas 13083-871, SP, Brazil.
Janaína Artem AtaideFaculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas 13083-871, SP, Brazil.ORCID 0000-0002-1929-9474
Jéssica Heline Lopes da FonsecaDepartment of Manufacturing and Materials Engineering, School of Mechanical Engineering, University of Campinas (Unicamp), Campinas 13083-860, SP, Brazil.ORCID 0000-0001-6931-3185
Luiza Aparecida Luna SilvérioFaculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas 13083-871, SP, Brazil.
Marcelo LancellottiFaculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas 13083-871, SP, Brazil.
Ana Cláudia Paiva-SantosDepartment of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0003-2710-6000
Marcos Akira d'ÁvilaDepartment of Manufacturing and Materials Engineering, School of Mechanical Engineering, University of Campinas (Unicamp), Campinas 13083-860, SP, Brazil.
Daniel S KohaneLaboratory for Biomaterials and Drug Delivery, Department of Anaesthesiology, Division of Critical Care Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Priscila Gava MazzolaFaculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas 13083-871, SP, Brazil.ORCID 0000-0002-3795-8189
Universidade Estadual de Campinas (UNICAMP) · BRBoston Children's Hospital · USRede de Química e Tecnologia · PT

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior Finance code 001National Council for Scientific and Technological Development 301436/2017-7São Paulo Research Foundation 2017/10728-2; 2018/06475-4; 2018/07707-454 6; 2018/05421-8
6 · The paper itself

Abstract

A poloxamer 407 (P407)-Casein hydrogel was chosen to carry polycaprolactone nanoparticles carrying terbinafine (PCL-TBH-NP). In this study, terbinafine hydrochloride (TBH) was encapsulated into polycaprolactone (PCL) nanoparticles, which were further incorporated into a poloxamer-casein hydrogel in a different addition order to evaluate the effect of gel formation. Nanoparticles were prepared by the nanoprecipitation technique and characterized by evaluating their physicochemical characteristics and morphology. The nanoparticles had a mean diameter of 196.7 ± 0.7 nm, PDI of 0.07, negative ζ potential (-0.713 mV), high encapsulation efficiency (>98%), and did not show cytotoxic effects in primary human keratinocytes. PCL-NP modulated terbinafine was released in artificial sweat. Rheological properties were analyzed by temperature sweep tests at different addition orders of nanoparticles into hydrogel formation. The rheological behavior of nanohybrid hydrogels showed the influence of TBH-PCL nanoparticles addition in the mechanical properties of the hydrogel and a long-term release of the nanoparticles from it.

Indexed as

drug releasehydrogelnanoparticlepoloxamer 407polycaprolactonerheologyterbinafine

Identifiers

PMID36986702
PMCPMC10056099
OpenAlexW4323313206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.